Rosiglitazone/Metformin
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 65 (11), 1581-1592
- https://doi.org/10.2165/00003495-200565110-00013
Abstract
▴ The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. ▴ Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control. A fixed-dose formulation of rosiglitazone/metformin was recently approved in the EU and the US for the treatment of type 2 diabetes mellitus in patients inadequately controlled on metformin monotherapy. ▴ Bioequivalence between the fixed-dose combination tablet and coadministration of rosiglitazone with metformin at the same dosage has been established in a pharmacokinetic study. ▴ Fixed-dose rosiglitazone/metformin 8mg/2g per day reduced glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels to a significantly greater extent than metformin 3 g/day in patients with type 2 diabetes in a 24-week, randomised, double-blind study. ▴ Rosiglitazone plus metformin was significantly more effective than metformin alone at reducing HbA1c and FPG levels in patients with type 2 diabetes in three 26-week, randomised, double-blind, placebo-controlled studies. ▴ Rosiglitazone plus metformin was generally well tolerated in all studies and had a tolerability profile similar to that of metformin monotherapy. Mild or moderate symptomatic hypoglycaemia was reported in ≤4.4% of rosiglitazone plus metformin recipients.Keywords
This publication has 31 references indexed in Scilit:
- Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysisClinical Therapeutics, 2004
- Effect of Rosiglitazone Versus Insulin on the Pancreatic β-Cell Function of Subjects With Type 2 DiabetesDiabetes Care, 2004
- AvandametBritish Journal of Diabetes, 2004
- Rosiglitazone plus metformin: combination therapy for Type 2 diabetesExpert Opinion on Pharmacotherapy, 2004
- Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretionAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- MetforminDrugs, 2003
- Thiazolidinediones in Type 2 Diabetes MellitusDrugs, 2003
- RosiglitazoneDrugs, 2002
- Lipotoxicity and glucotoxicity in type 2 diabetesPostgraduate Medicine, 2001